- Home
- ABL vs XNCR Comparison
ABL vs XNCR Comparison
Compare ABL & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABL
- XNCR
- Stock Information
- Founded
- ABL 2004
- XNCR 1997
- Country
- ABL United States
- XNCR United States
- Employees
- ABL N/A
- XNCR N/A
- Industry
- ABL Investment Managers
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- ABL Finance
- XNCR Health Care
- Exchange
- ABL Nasdaq
- XNCR Nasdaq
- Market Cap
- ABL 559.5M
- XNCR 579.3M
- IPO Year
- ABL N/A
- XNCR 2013
- Fundamental
- Price
- ABL $5.49
- XNCR $8.54
- Analyst Decision
- ABL Strong Buy
- XNCR Buy
- Analyst Count
- ABL 4
- XNCR 7
- Target Price
- ABL $13.63
- XNCR $27.50
- AVG Volume (30 Days)
- ABL 1.7M
- XNCR 855.3K
- Earning Date
- ABL 08-11-2025
- XNCR 08-04-2025
- Dividend Yield
- ABL N/A
- XNCR N/A
- EPS Growth
- ABL N/A
- XNCR N/A
- EPS
- ABL N/A
- XNCR N/A
- Revenue
- ABL $134,575,948.00
- XNCR $127,228,000.00
- Revenue This Year
- ABL $68.84
- XNCR N/A
- Revenue Next Year
- ABL $26.84
- XNCR $28.84
- P/E Ratio
- ABL N/A
- XNCR N/A
- Revenue Growth
- ABL 73.39
- XNCR N/A
- 52 Week Low
- ABL $5.10
- XNCR $7.16
- 52 Week High
- ABL $11.86
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- ABL 25.95
- XNCR 44.94
- Support Level
- ABL $5.43
- XNCR $8.05
- Resistance Level
- ABL $6.24
- XNCR $10.20
- Average True Range (ATR)
- ABL 0.61
- XNCR 0.57
- MACD
- ABL -0.09
- XNCR -0.01
- Stochastic Oscillator
- ABL 13.57
- XNCR 31.40
About ABL Abacus Life Inc.
Abacus Global Management Inc is a financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. The Company organizes its business into five reportable segments Active Management, Originations, Asset Management, Portfolio Servicing, and Technology Services. Its operations are confined to the United States.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.